Abstract
Anti-tumor immune responses are mediated primarily by T cells. Down regulation of major histocompatiblity complex (MHC) and the molecules that costimulate the immune responses is associated with defective signaling of tumor cells for T cell activation. In vitro fusion of autologous tumor cells with antigen presenting cells (APCs) or treatment of tumor cells with a combination of cytokines significantly increased the expression of MHC class I and adhesion molecules on tumor cell surfaces that costimulate host immune responses. The hybrid cells generated by fusion of tumor cells with APCs and the tumor cells treated in vitro with a combination of cytokines and pre-incubated with a bispecific monoclonal antibody (bi-Mab) cross-linking antigen on tumor cells to CD28 on T cells, become immunogenic and able to stimulate naive T cells with generation of tumor specific cytotoxic T cells both in vitro and in vivo. Immunization with the modified tumor cells elicits an immune response mediated by both CD4+ and CD8+ T cells. This response protected against a parental tumor cell challenge and cured established tumors. The approach was effective in both low immunogenic and non-immunogenic tumor systems. Modification of tumor cells with tumor:APC fusion or the two-step procedure may provide a strategy for development of tumor vaccines that is effective for cancer immunotherapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Restifo, N.P. and Wunderlich, J.R. Biology of cellular Immune responses. Biological Therapy of Cancer. 2nd edition, DeVita, V.T. Jr, Hellman, S. and Rosenberg, S.A. Editors. J.B. Lippincott Co., Philadelphia, Chapter 1, 3–37 (1995).
Chen, L. et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4. Cell 71, 1093–1102 (1992).
June, C.H., Bluestone, J.A., Nadler, L.M. and Thompsom, C.B. The B7 and CD28 receptor families. Immunol. Today. 15, 321–331 (1994).
Townsend, S.E. and Allison, J.R Tumor rejection after direct costimulation of CD8+ T cells by B7 transfected melanoma cells. Science 259, 368–370 (1993).
Allison, J.P. CD28-B7 interactions in T cell activation. Curr. Opin. Immunol. 6, 414–419 (1994).
Schwartz, R.H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065–1068 (1992).
Harding, F.A., McArthur, J.G., Gross, J.A., Raulet, D.H. and Allison, J.P. CD28-mediated signaling costimulates murine T cells and prevent induction of anergy in T cell clones. Nature 356, 607–609 (1992).
Yang, G., Hellström, K.E., Hellström, I. and Chen, L. Antitumor immunity elicited by tumor cells transfected with B7–2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794–2800 (1995).
Marincola, F.M. et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 153, 1225–1237 (1994).
Luboldt, H., Britta, S.K., Rubben, H. and Grosse-Wilde, H. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res. 56, 826–830 (1996).
Wallich, R., Bulbuc, N., Hammerling, G.J., Katzav, S., Segal, S. and Feldman, M. Abrogation of metastatic properties of tumor by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315, 301–305 (1985).
Li, Y., Hellström K.E., Newby, S.A. and Chen, L.P. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J. Exp. Med. 183, 639–644 (1996).
Yang, G., Helloström, K.E., Mizuno, M.T. and Chen, L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immunol. 155, 3897–3903 (1995).
Berman, R.M. et al. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J. Immunol. 157, 231–238 (1996).
Walunas, T.L., Lenschow, D.L., Bakker, C.Y., Linsley, P., Freeman, G.J., Green, J.M., Thompson, C.B. and Bluestone, J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405–413 (1994).
Krummel, M.F. and Allison, J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533–2540 (1996).
Walunas, T.L., Bakker, C.Y. and Bluestone, J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183, 2541–2550 (1996).
Tivol, E.A., Bordello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A. and Sharpe, A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3, 541–547(1995).
Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 985–988 (1995).
Leach, D.R., Krummel, M.K. and Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736(1996).
Guo, Y.J. et al. Effective vaccine generated by fusion of hepatoma cells with B cells. Science 263, 518–520 (1994).
Grabbe, S., Beissert, S., Schwarz, T and Granstein, R.D. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy. Immunol. Today 16, 117–121 (1995).
Renner, C. et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human tumor cells. Science 264, 833–835 (1994).
Kroesen, J., Bakker, A., Van Lier, R.A.W., The, H.T. and Leij, L.D. Bispecifc antibody-mediated target cell specific costimulation of resting T cells. Cancer Res. 55, 4409–4415 (1995).
Darlington, G.J., Bernhard, H.P., Miller, R.A. and Ruddle, F.H. Expression of liver phenotypes in cultured mouse hepatoma cells. J. Natl. Cancer Inst. 64, 809 (1980).
MacLean, J.A., Su, Z.L., Guo, Y.J., Sy, M.S., Colvin, R.B and Wong, J.T. Anti- CD3:Anti-IL-2 receptor bispecific monoclonal antibody targeting of activated T cells in vitro. J. Immunol. 150, 1619–1628 (1993).
Huang, A.Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitzky, H. Role of bone marrow-derived cells in presenting MHC class I restricted tumor antigen. Science 264, 961–965 (1994).
Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52–58 (1996).
Guo, Y.J. et al. Inhibition of human melanoma growth and metastasis in vitro by anti-CD44 monoclonal antibody. Cancer Res. 54, 1561–1565 (1994).
Takahashi, H., Nakada, T. and Puisieux, I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in scid mice. Science 259, 1460–1463 (1993).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wu, S. et al. (1998). Treatment of Hepatocellular Carcinoma with the Cellular Tumor Vaccines Generated by in Vitro Modification of Tumor Cells with Non Gene Transfer Approaches. In: Walden, P., Trefzer, U., Sterry, W., Farzaneh, F., Zambon, P. (eds) Gene Therapy of Cancer. Advances in Experimental Medicine and Biology, vol 451. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5357-1_45
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5357-1_45
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7444-2
Online ISBN: 978-1-4615-5357-1
eBook Packages: Springer Book Archive